Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicityYunqian Qiao, Xuan Wang(Innovative Biologics (United States))Nature CommunicationsNovember 4, 202110.1038/s41467-021-26645-6Cited by 40SaveCiteExport RISWatch citationsRelated PapersA dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor|Theranostics|2023|23